4.6 Review

Movement disorders in catatonia

期刊

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/jnnp-2014-309098

关键词

-

资金

  1. Adamas Pharmaecuticals, Inc
  2. Allergan, Inc
  3. Auspex Pharmaceuticals, Inc [5D809]
  4. CHDI Foundation
  5. GE Healthcare
  6. Great Lakes NeuroTechnologies
  7. Huntington's Disease Society of America
  8. Huntington Study Group
  9. Ipsen Limited
  10. Kyowa Haako Kirin Pharma, Inc
  11. Lundbeck Inc
  12. Medtronic
  13. Merz Pharmaceuticals
  14. Michael J Fox Foundation for Parkinson Research
  15. National Institutes of Health
  16. National Parkinson Foundation
  17. Omeros Corporation [OMS824]
  18. Parkinson Study Group
  19. Pharma Two B
  20. Prothena Biosciences Inc [PRX002]
  21. Psyadon Pharmaceuticals (ecopipam), Inc
  22. St. Jude Medical
  23. Teva Pharmaceutical Industries Ltd
  24. UCB Inc
  25. University of Rochester

向作者/读者索取更多资源

Catatonia is a complex neuropsychiatric syndrome characterised by a broad range of motor, speech and behavioural abnormalities. 'Waxy flexibility', 'posturing' and 'catalepsy' are among the well-recognised motor abnormalities seen in catatonia. However, there are many other motor abnormalities associated with catatonia. Recognition of the full spectrum of the phenomenology is critical for an accurate diagnosis. Although controlled trials are lacking benzodiazepines are considered first-line therapy and N-Methyl-oaspartate receptor antagonists also appears to be effective. Electroconvulsive therapy is used in those patients who are resistant to medical therapy. An underlying cause of the catatonia should be identified and treated to ensure early and complete resolution of symptoms.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据